Allurion Technologies plans to launch a clinical study combining its weight-loss program with GLP-1 agonists to address muscle loss, a common side effect of GLP-1 therapy. Existing research indicates that GLP-1 treatments can lead to a 40% reduction in lean mass as part of overall weight loss, while the Allurion Balloon, combined with its virtual care platform, has shown positive results in weight reduction while preserving or even increasing muscle mass. For instance, one study showed patients gained 5.6% lean body mass while losing 14% of their total weight, and another showed a 15.7% weight reduction with no muscle mass change.
This study holds considerable potential for advancing obesity treatment. By tackling the issue of muscle loss associated with GLP-1 therapies, Allurion could significantly enhance the metabolic benefits of these medications. This could lead to a more comprehensive and effective approach to weight management, potentially positioning the combined therapy as a preferred option for patients and healthcare providers.
The planned study aims to demonstrate that combining the Allurion Program (balloon, virtual care suite, and connected scale) with GLP-1 therapy can result in substantial weight loss while simultaneously increasing muscle mass and improving overall body composition. This builds upon previous studies showcasing the Allurion Balloon’s ability to facilitate weight loss while preserving lean mass, contrasted with the muscle loss observed in GLP-1 therapies.
This research could reshape the landscape of obesity care. Positive results could establish this combination therapy as a new standard, offering a more holistic and potentially safer weight-loss strategy that addresses a key drawback of current GLP-1 treatments. This could further solidify Allurion’s position in the market and broaden the applicability of GLP-1 medications for a wider range of patients seeking effective and metabolically healthy weight loss.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.